BROMANASE 1800 TAB 225MG 225 MG — DIN 00621692
BROMELAIN : 225 MG · NF FORMULAS INC. · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is BROMANASE 1800 TAB 225MG?
BROMANASE 1800 TAB 225MG 225 MG contains BROMELAIN : 225 MG. It is listed in the Health Canada Drug Product Database under DIN 00621692, held by NF FORMULAS INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 21-Jun-2000. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Bromelains in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Bromelains, across 11 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NF FORMULAS INC. | 2 | 0 | BROMANASE 1800 TAB 225MG, RF TAB DIGESTIVE AID 100MG | No marketed DIN |
| ALBI IMPORTS LTD. | 1 | 0 | BROMELAIN TAB 50MG | No marketed DIN |
| ALBI NATURALS | 1 | 0 | ROCKY MOUNTAIN BROMELAIN CAP 500MG | No marketed DIN |
| COUNTRY HEALTH LABORATORIES LTD. | 1 | 0 | BROMELAIN TAB 50MG | No marketed DIN |
| EVEREST PHARMACEUTICALS LTD. | 1 | 0 | BROMELAIN PWR | No marketed DIN |
| JAMIESON LABORATORIES LTD | 1 | 0 | BROMELAIN 500MG TABLETS | No marketed DIN |
| NU-LIFE NUTRITION LTD. | 1 | 0 | BROMELAIN PINEAPPLE ENZYME 50 MG NU LIFE | No marketed DIN |
| QUEST VITAMINS A DIV OF PURITY LIFE HEALTH PRODUCTS | 1 | 0 | BROMELAIN 500 (300GDU/CAPSULE) | No marketed DIN |
| ROYAL BODYCARE CANADA INC. | 1 | 0 | BROMELAIN TABLET 500MG | No marketed DIN |
| THORNE RESEARCH INC. | 1 | 0 | BROMELAIN 250 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 225 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Bromelains |
|---|---|
| ATC code | B06AA11 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00621692 |
|---|---|
| DIN (unpadded, as printed on some documents) | 621692 |
| Brand name | BROMANASE 1800 TAB 225MG |
| Generic / active ingredient | BROMELAIN : 225 MG |
| Market authorization holder | NF FORMULAS INC. |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | B06AA11 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B06AA |
| Current status | CANCELLED POST MARKET |
| Status date | 21-Jun-2000 |
| Original market date | 1984-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BROMELAIN 250 | 250 MG | CAPSULE | THORNE RESEARCH INC. | CANCELLED POST MARKET | 00634670 |
| BROMELAIN 500 (300GDU/CAPSULE) | 500 MG | CAPSULE | QUEST VITAMINS A DIV OF PURITY LIFE HEALTH PRODUCTS | CANCELLED POST MARKET | 02034735 |
| BROMELAIN 500MG TABLETS | 500 MG | TABLET | JAMIESON LABORATORIES LTD | CANCELLED POST MARKET | 02147378 |
| BROMELAIN PINEAPPLE ENZYME 50 MG NU LIFE | 50 MG | TABLET | NU-LIFE NUTRITION LTD. | CANCELLED POST MARKET | 00063436 |
| BROMELAIN PWR | 20 MG | POWDER | EVEREST PHARMACEUTICALS LTD. | CANCELLED POST MARKET | 00491551 |
| BROMELAIN TAB 50MG | 50 MG | TABLET | ALBI IMPORTS LTD. | CANCELLED POST MARKET | 00494968 |
| BROMELAIN TAB 50MG | 50 MG | TABLET | COUNTRY HEALTH LABORATORIES LTD. | CANCELLED POST MARKET | 00532150 |
| BROMELAIN TABLET 500MG | 500 MG | TABLET | ROYAL BODYCARE CANADA INC. | CANCELLED POST MARKET | 02057360 |
| RF TAB DIGESTIVE AID 100MG | 100 MG | TABLET | NF FORMULAS INC. | CANCELLED POST MARKET | 00605042 |
| ROCKY MOUNTAIN BROMELAIN CAP 500MG | 500 MG | CAPSULE | ALBI NATURALS | CANCELLED POST MARKET | 02052725 |
2 · Same class — other molecules in ATC B06AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Bromelains | BROMANASE 1800 TAB 225MG · BROMELAIN 250 · BROMELAIN 500 (300GDU/CAPSULE) · BROMELAIN 500MG TABLETS · +6 more | 11 | 0 | Not in Canada |
| Hyaluronidase | WYDASE INJ 150UNIT/ML · WYDASE INJECTION LIQ 150 UNITS/ML | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B06AC | Berotralstat · C1-Inhibitor, Plasma Derived · Garadacimab · Icatibant · Lanadelumab | 16 | 10 |
| B06AB | Hematin | 1 | 1 |
| B06AX | Exagamglogene Autotemcel | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.